Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Mercaptopurine (Xaluprine®) 20 mg/ml oral suspension is recommended as an option for use within NHS Wales for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children. |
|||
|
|||
Medicine details |
|||
| Medicine name | mercaptopurine (Xaluprine®) | ||
| Formulation | 20 mg/ml oral suspension | ||
| Reference number | 1252 | ||
| Indication | Treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children |
||
| Company | Nova Laboratories Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 2412 | ||
| NMG meeting date | 10/07/2012 | ||
| AWMSG meeting date | 12/09/2012 | ||
| Ratification by Welsh Government | 25/10/2012 | ||
| Date of issue | 25/10/2012 | ||
| Date of last review | December 2022 | ||
| Further information This appraisal recommendation was reviewed in December 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |
|||